Discontinued — last reported Q1 '26
Isentress/Isentress HD — Sales
Merck & Co. Isentress/Isentress HD — Sales decreased by 56.3% to $59.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 67.2%, from $180.00M to $59.00M. Over 4 years (FY 2021 to FY 2025), Isentress/Isentress HD — Sales shows a downward trend with a -19.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase in sales indicates strong market retention or successful clinical positioning, while a decrease typically signals the impact of patent expirations, generic competition, or a shift in physician prescribing patterns toward newer therapeutic alternatives.
Detailed definition
This metric represents the total annual revenue generated from the global sales of the Isentress and Isentress HD produc...
Peer comparison
Comparable to revenue metrics for mature, legacy pharmaceutical products or specific therapeutic franchises within the portfolios of other major biopharmaceutical companies.
mrk_segment_isentress_isentress_hd_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $384.00M | $378.00M | $357.00M | $316.00M | $294.00M | $322.00M | $334.00M | $246.00M | $272.00M | $238.00M | $210.00M | $222.00M | $178.00M | $204.00M | $184.00M | $180.00M | $172.00M | $163.00M | $135.00M | $59.00M |
| QoQ Change | — | -1.6% | -5.6% | -11.5% | -7.0% | +9.5% | +3.7% | -26.3% | +10.6% | -12.5% | -11.8% | +5.7% | -19.8% | +14.6% | -9.8% | -2.2% | -4.4% | -5.2% | -17.2% | -56.3% |
| YoY Change | — | — | — | — | -23.4% | -14.8% | -6.4% | -22.2% | -7.5% | -26.1% | -37.1% | -9.8% | -34.6% | -14.3% | -12.4% | -18.9% | -3.4% | -20.1% | -26.6% | -67.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s isentress/isentress hd — sales?
- Merck & Co. (MRK) reported isentress/isentress hd — sales of $59.00M in Q1 2026.
- How has Merck & Co.'s isentress/isentress hd — sales changed year-over-year?
- Merck & Co.'s isentress/isentress hd — sales decreased by 67.2% year-over-year, from $180.00M to $59.00M.
- What is the long-term trend for Merck & Co.'s isentress/isentress hd — sales?
- Over 4 years (2021 to 2025), Merck & Co.'s isentress/isentress hd — sales has grown at a -19.4% compound annual growth rate (CAGR), from $1.54B to $650.00M.
- What does isentress/isentress hd — sales mean?
- The total annual revenue generated from the sale of the company's HIV-1 treatment medication, Isentress and its high-dose variant.